POTASSIUM AMINOSALICYLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM AMINOSALICYLATE (POTASSIUM AMINOSALICYLATE).
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
| Metabolism | Hepatic (acetylation to N-acetyl-4-aminosalicylic acid and other metabolites); also undergoes intestinal metabolism by gut bacteria. |
| Excretion | Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%. |
| Half-life | 0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment. |
| Protein binding | 50-60% bound to albumin. |
| Volume of Distribution | 0.2-0.4 L/kg; reflects distribution into total body water with limited tissue penetration. |
| Bioavailability | Oral: ~90% absorbed; food may delay absorption. |
| Onset of Action | Oral: 2-4 weeks for bacteriostatic effect in tuberculosis; topical: not applicable. |
| Duration of Action | Dosing every 6-8 hours required due to rapid elimination; sustained effect requires consistent serum levels. |
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
| Dosage form | POWDER |
| Renal impairment | GFR <50 mL/min: not recommended due to risk of accumulation; if unavoidable, reduce dose to 4 g once daily. GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% (to 2 g twice daily). Child-Pugh Class C: avoid use. |
| Pediatric use | Children: 200-300 mg aminosalicylic acid base per kg body weight per day, divided into 2 doses. Maximum 8 g/day. |
| Geriatric use | Start at lower end of dosing (4 g once daily) due to potential decreased renal function and increased risk of gastrointestinal intolerance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM AMINOSALICYLATE (POTASSIUM AMINOSALICYLATE).
| Breastfeeding | Excreted in breast milk; M/P ratio unknown. Caution due to potential for infant methemoglobinemia or gastrointestinal disturbances. |
| Teratogenic Risk | First trimester: Insufficient data; no known human teratogenicity but animal studies inconclusive. Second/third trimester: No documented fetal harm; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to any salicylate component","Severe hepatic disease","Severe renal impairment (eGFR < 30 mL/min)"]
| Precautions | ["Hypersensitivity reactions including fever and rash","Hepatotoxicity (discontinue if jaundice or liver enzyme elevation occurs)","Renal impairment may require dose adjustment","Gastrointestinal intolerance","May cause hypocalcemia and hypokalemia","Interference with thyroid function tests"] |
Loading safety data…
| Monitor serum potassium levels, renal function, and signs of GI intolerance. For fetus: ultrasound for growth and amniotic fluid volume. |
| Fertility Effects | No known effects on fertility in human studies. |